Vis enkel innførsel

dc.contributor.authorBoskovic, Miroslav
dc.contributor.authorJortveit, Jarle
dc.contributor.authorHaraldsen, Marius Blørstad
dc.contributor.authorBerge, Trygve
dc.contributor.authorEngdahl, Johan
dc.contributor.authorLøchen, Maja-Lisa
dc.contributor.authorSchuster, Peter Moritz
dc.contributor.authorSandberg, Edvard Liljedahl
dc.contributor.authorGrimsmo, Jostein
dc.contributor.authorAtar, Dan
dc.contributor.authorAnfinsen, Ole-Gunnar
dc.contributor.authorPripp, Are Hugo
dc.contributor.authorGrenne, Bjørnar Leangen
dc.contributor.authorHalvorsen, Sigrun
dc.date.accessioned2024-10-24T06:43:03Z
dc.date.available2024-10-24T06:43:03Z
dc.date.issued2024-09-09
dc.description.abstractAims Atrial fibrillation (AF) is a common arrhythmia, and many cases of AF may be undiagnosed. Whether screening for AF and subsequent treatment if AF is detected can improve long-term outcome remains an unsettled question. The primary aim of the NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial is to assess whether self-screening for AF with continuous electrocardiogram (ECG) for 3–7 days in individuals aged 65 years or older with at least one additional risk factor for stroke, and initiation of guideline-recommended therapy in patients with detected AF, will reduce the occurrence of stroke.<p> <p>Methods and results This study is a nationwide open, siteless, randomized, controlled trial. Individuals ≥65 years of age are randomly identified from the National Population Register of Norway and are invited to take a digital inclusion/exclusion test. Individuals passing the inclusion/exclusion test are randomized to either the intervention group or the control group. A total of 35 000 participants will be enrolled. In the intervention group, self-screening is performed continuously over 3–7 days at home with a patch ECG device (ECG247) at inclusion and after 12–18 months. If AF is detected, guideline-recommended therapy will be initiated. Patients will be followed up for 5 years through national health registries. The primary outcome is time to a first stroke (ischaemic or haemorrhagic stroke). The first participant in the NORSCREEN trial was enrolled on 1 September 2023. <p>Conclusion The results from the NORSCREEN trial will provide new insights regarding the efficacy of digital siteless self-screening for AF with respect to stroke prevention in individuals at an increased risk of stroke.en_US
dc.identifier.citationBoskovic, Jortveit, Haraldsen, Berge, Engdahl, Løchen, Schuster, Sandberg, Grimsmo, Atar, Anfinsen, Pripp, Grenne, Halvorsen. The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trial. Europace. 2024;26(10)en_US
dc.identifier.cristinIDFRIDAID 2313433
dc.identifier.doi10.1093/europace/euae228
dc.identifier.issn1099-5129
dc.identifier.issn1532-2092
dc.identifier.urihttps://hdl.handle.net/10037/35320
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.relation.journalEuropace
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0en_US
dc.rightsAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)en_US
dc.titleThe NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trialen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)